NASDAQ:SLS SELLAS Life Sciences Group - SLS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.43 +0.05 (+3.62%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.40▼$1.4850-Day Range$1.18▼$3.8652-Week Range$1.17▼$7.37Volume229,202 shsAverage Volume489,215 shsMarket Capitalization$40.47 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SELLAS Life Sciences Group MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside389.5% Upside$7.00 Price TargetShort InterestHealthy4.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.66) to ($0.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector576th out of 1,004 stocksPharmaceutical Preparations Industry277th out of 489 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, SELLAS Life Sciences Group has a forecasted upside of 389.5% from its current price of $1.43.Amount of Analyst CoverageSELLAS Life Sciences Group has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.31% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently decreased by 5.43%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 2.8 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.Search InterestOnly 6 people have searched for SLS on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows3 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 10.65% of the stock of SELLAS Life Sciences Group is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to decrease in the coming year, from ($0.66) to ($0.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 6.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SELLAS Life Sciences Group (NASDAQ:SLS) StockSELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.Read More Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Stock News HeadlinesMarch 24, 2023 | americanbankingnews.comCantor Fitzgerald Comments on SELLAS Life Sciences Group, Inc.'s FY2023 Earnings (NASDAQ:SLS)March 18, 2023 | markets.businessinsider.comMaxim Group Remains a Buy on SELLAS Life Sciences Group (SLS)April 1, 2023 | Vantage Point (Ad)The Market Crash Shield is A.I.Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. March 17, 2023 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business UpdateMarch 16, 2023 | msn.comSELLAS Life Sciences GAAP EPS of -$2.13 misses by $0.03, revenue of $1M in-lineMarch 16, 2023 | finance.yahoo.comSELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business UpdateMarch 7, 2023 | finance.yahoo.comSELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed JournalFebruary 24, 2023 | msn.comWhy Sellas Life Sciences Shares Are NosedivingApril 1, 2023 | Vantage Point (Ad)The Market Crash Shield is A.I.Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. February 24, 2023 | finance.yahoo.comSELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public OfferingFebruary 24, 2023 | finance.yahoo.comSellas Life Sciences raises $20 million from public offering of stock, warrantsFebruary 24, 2023 | finance.yahoo.comSellas Lift Sciences stock plunges to pace premarket decliners after stock, warrants offeringFebruary 5, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn SituationJanuary 19, 2023 | finance.yahoo.comSELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia ProgramJanuary 5, 2023 | finance.yahoo.comSELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory AffairsDecember 13, 2022 | finance.yahoo.comSELLAS Life Sciences Highlights Data From Early Study In Blood Cancer PatientsDecember 13, 2022 | finance.yahoo.comSELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic MalignanciesDecember 8, 2022 | msn.comLooking Into SELLAS Life Sciences Gr's Recent Short InterestDecember 8, 2022 | technews.tmcnet.comSELLAS Life Sciences' Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as PlannedDecember 8, 2022 | finance.yahoo.comSELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as PlannedDecember 6, 2022 | finance.yahoo.comSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer InstituteDecember 1, 2022 | finance.yahoo.comSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine ModelNovember 30, 2022 | finance.yahoo.comSELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology SummitNovember 16, 2022 | finance.yahoo.comSELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)November 15, 2022 | finance.yahoo.comSELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than AnticipatedNovember 14, 2022 | finance.yahoo.comSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comSELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid LeukemiaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address SLS Company Calendar Last Earnings11/12/2021Today4/01/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees7Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$8.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+389.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net MarginsN/A Pretax Margin-4,130.10% Return on Equity-407.61% Return on Assets-164.24% Debt Debt-to-Equity RatioN/A Current Ratio1.14 Quick Ratio1.14 Sales & Book Value Annual Sales$1 million Price / Sales40.47 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book6.22Miscellaneous Outstanding Shares28,300,000Free Float27,992,000Market Cap$40.47 million OptionableNot Optionable Beta2.30 Key ExecutivesAngelos M. StergiouPresident, Chief Executive Officer & DirectorJohn T. BurnsSVP, Chief Financial Officer & Accounting OfficerDragan CicicSenior Vice President-Clinical DevelopmentBarbara A. WoodSecretary, Executive VP & General CounselAndrew ElnatanVP, Head-Regulatory Affairs & ChemistryKey CompetitorsRenovoRxNASDAQ:RNXTYumanity TherapeuticsNASDAQ:YMTXTonix PharmaceuticalsNASDAQ:TNXPASLAN PharmaceuticalsNASDAQ:ASLNOrgenesisNASDAQ:ORGSView All CompetitorsInstitutional OwnershipMillennium Management LLCBought 36,396 shares on 2/15/2023Ownership: 0.298%Virtu Financial LLCBought 18,379 shares on 2/15/2023Ownership: 0.089%Susquehanna International Group LLPSold 13,400 shares on 2/14/2023Ownership: 0.000%Geode Capital Management LLCBought 43,347 shares on 2/13/2023Ownership: 0.915%Wells Fargo & Company MNBought 5,004 shares on 2/13/2023Ownership: 0.079%View All Institutional Transactions SLS Stock - Frequently Asked Questions Should I buy or sell SELLAS Life Sciences Group stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SLS shares. View SLS analyst ratings or view top-rated stocks. What is SELLAS Life Sciences Group's stock price forecast for 2023? 2 equities research analysts have issued 1 year target prices for SELLAS Life Sciences Group's stock. Their SLS share price forecasts range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $7.00 in the next year. This suggests a possible upside of 389.5% from the stock's current price. View analysts price targets for SLS or view top-rated stocks among Wall Street analysts. How have SLS shares performed in 2023? SELLAS Life Sciences Group's stock was trading at $2.36 on January 1st, 2023. Since then, SLS shares have decreased by 39.4% and is now trading at $1.43. View the best growth stocks for 2023 here. When is SELLAS Life Sciences Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our SLS earnings forecast. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.09. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group shares reverse split before market open on Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What is SELLAS Life Sciences Group's stock symbol? SELLAS Life Sciences Group trades on the NASDAQ under the ticker symbol "SLS." How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SELLAS Life Sciences Group's stock price today? One share of SLS stock can currently be purchased for approximately $1.43. How much money does SELLAS Life Sciences Group make? SELLAS Life Sciences Group (NASDAQ:SLS) has a market capitalization of $40.47 million and generates $1 million in revenue each year. The company earns $-41,300,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. How can I contact SELLAS Life Sciences Group? SELLAS Life Sciences Group's mailing address is 15 WEST 38TH STREET 10TH FLOOR, NEW YORK NY, 10018. The official website for the company is www.sellaslifesciences.com. The company can be reached via phone at (646) 200-5278, via email at ir@sellaslife.com, or via fax at 441-400-2875. This page (NASDAQ:SLS) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.